MRD-Driven Daratumumab: Phase 2 Results in New Myeloma

원문 링크: WordPress 원문

Researchers at the University of Michigan Rogel Cancer Center posted results on ClinicalTrials.gov on July 28, 2026 , showing that an MRD-driven adaptive daratumumab-based strategy achieved minimal residual disease negativity in 15 of 50 efficacy-evaluable patients with newly diagnosed multiple myeloma . The single-group phase 2 design without a randomised comparator and the registry-level reporting leave the comparative benefit and generalisability uncertain , though the results provide early evidence that MRD-guided treatment adaptation is feasible in a daratumumab-based backbone .

The results table for this phase 2 trial was first posted on ClinicalTrials.gov on July 28, 2026, making the primary endpoint data publicly available before any peer-reviewed publication .

15 / 50

MRD negativity (primary)

57

Patients enrolled

Phase 2

Trial phase

English

한국어

MRD negativity reached in 15 of 50 evaluable patients

Design: Single-group, open-label, phase 2 treatment study.

Enrolled: 57 participants enrolled; 1 did not start treatment.

Analysis population: 50 of 57 enrolled patients evaluable for efficacy.

Primary endpoint: MRD negativity after induction or consolidation at week 36.

Of the 57 participants enrolled in this single-group study, 50 were evaluable for the primary efficacy analysis. Among these 50 patients, 15 achieved minimal residual disease negativity as assessed by International Myeloma Working Group response criteria at the end of week 36, following either induction therapy alone or induction plus consolidation for those who remained MRD-positive after induction. The treatment backbone consisted of daratumumab combined with lenalidomide and dexamethasone during induction, with bortezomib added during consolidation for MRD-positive patients, followed by daratumumab-lenalidomide maintenance. The MRD-driven adaptive design meant that treatment intensity was escalated only for patients who had not achieved MRD negativity after the initial induction phase, sparing MRD-negative patients from additional bortezomib exposure. The primary completion date was recorded as May 2, 2024, and the overall study status is listed as active but not recruiting. The adaptive escalation rule meant that only patients failing to clear MRD after induction received additional bortezomib, concentrating toxicity exposure where it was most likely to add value. This selective intensification is a central feature of the study rationale and distinguishes it from fixed-duration regimens.

AI-generated conceptual illustration; not study data.

MRD-guided adaptation could refine myeloma treatment intensity

Minimal residual disease has emerged as one of the most prognostically meaningful endpoints in multiple myeloma, with MRD-negative patients consistently showing longer progression-free and overall survival across multiple trials. The concept of using MRD status to guide treatment decisions, escalating therapy for MRD-positive patients and potentially de-escalating for MRD-negative patients, represents a shift toward precision medicine in a disease where treatment intensity has historically been applied uniformly. Daratumumab, an anti-CD38 monoclonal antibody, has become a cornerstone of myeloma therapy, and demonstrating that an MRD-driven adaptive strategy is feasible within a daratumumab-based backbone provides a framework for future randomised trials. The 30% MRD negativity rate observed in this cohort should be interpreted cautiously given the absence of a comparator arm, but it establishes a signal that warrants further investigation in larger, controlled settings. The inclusion of both transplant-eligible and transplant-ineligible patients broadens the potential applicability of the findings. If validated, such an approach could reduce overtreatment for patients who already achieve deep responses while reserving additional therapy for those who need it most. That balance between efficacy and tolerability is a major goal of contemporary myeloma care.

Registry-level reporting and single-group design constrain interpretation

These results were posted on ClinicalTrials.gov as a registry entry rather than as a peer-reviewed publication, which means they have not undergone independent editorial and methodological scrutiny. The single-group design precludes any direct comparison with standard fixed-duration therapy or alternative MRD-guided approaches. Several secondary endpoints, including overall survival and progression-free survival, are listed as not posted, leaving critical long-term outcomes unreported. Adverse event data indicate that 25 of 56 participants in the event group experienced serious adverse events through four years of follow-up, but detailed term-level safety tables are not available in the posted record. The MRD assessment methodology, while specified as IMWG criteria, may not be directly comparable to next-generation sequencing or next-generation flow approaches used in other trials. Seven enrolled patients were not evaluable for efficacy, and the reasons for non-evaluability are not detailed in the posted results. The study was conducted at a single academic centre, limiting generalisability to community practice settings. These caveats do not invalidate the signal, but they do mean the results should be viewed as hypothesis-generating rather than practice-changing until confirmed by controlled data and fuller safety reporting.

AI-generated conceptual illustration; not study data.

Peer-reviewed publication and randomised confirmation are needed

The most immediate next step is the publication of these results in a peer-reviewed journal, where the methodology, patient disposition, and safety data can be independently evaluated. Randomised phase 3 trials comparing MRD-driven adaptive therapy against standard fixed-duration daratumumab-based regimens will be necessary to determine whether this strategy improves long-term outcomes without adding unnecessary toxicity. The myeloma research community is actively investigating MRD-guided approaches in several ongoing trials, and the results from this phase 2 study will contribute to the evidence base informing those larger efforts. Patients should understand that a registry posting does not constitute a confirmed clinical benefit, and that treatment decisions should be based on established guidelines and individual clinical circumstances rather than early-phase single-arm data. The University of Michigan Rogel Cancer Center team is expected to present updated analyses at upcoming haematology conferences as longer follow-up data mature. In the interim, clinicians should weigh these registry findings alongside established guideline recommendations and the individual circumstances of each patient before altering any treatment plan.

This article reports results posted on a clinical trial registry, not a peer-reviewed publication. A single-group phase 2 design without a randomised comparator cannot establish comparative efficacy. Registration of results does not equal confirmed clinical benefit. MRD negativity is a prognostic biomarker and does not constitute a diagnosis of cure.

References

ClinicalTrials.gov: NCT04140162 — MRD-driven adaptive myeloma study

PubMed: PMID 35285981 — Supporting publication

This content is for informational purposes only and is not medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional. Registry posting does not equal confirmed clinical benefit. Authorisation in one jurisdiction does not imply approval elsewhere.